At the news
? BEARISHIMPACT 8/10 8-K filed Sep 2, 2026 at 16:04 ET
Ultragenyx announced that its Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome failed to meet the primary endpoint (Bayley-4 cognitive raw score) and the key secondary endpoint (MDRI). The company will evaluate the program's disposition and implement significant expense reductions while supporting its commercial business. This is a major pipeline setback for a company with a $2.5B market cap that was likely pricing in some probability of success for this high-profile asset.
- Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score.
- The study also failed the key secondary endpoint of net response in Multidomain Responder Index (MDRI).
- No differences were observed between treated and control groups supporting efficacy in Bayley Cognition raw scores or MDRI.
- Safety profile was consistent with Phase 1/2.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access